Zydus Cadila gets approval for liver disease drug

Zydus Cadila, a part of Cadila Healthcare, today informed the bourses that it has received an approval from Drug Controller General of India (DCGI) for its New Drug Application (NDA).

This new drug application is for Saroglitazar and used in the treatment of Non-Cirrhotic Non-Alcoholic SteatoHepatitis (NASH) in India.

The company had filed an application for the abovementioned drug in December 2019. This has now become the first globally indicated drug for the treatment of NASH. Otherwise, there was no treatment available for this progressive liver disease.

Cadila's FY19 revenue mix comprised of US Formulations (50 per cent), India Formulations (29 per cent), EMB Formulations (six per cent), Animal Health (four per cent), Wellness (four per cent), API (three per cent), Alliances (two per cent) and Europe Formulations (two per cent).

Today, the stock of Cadila Healthcare gained nearly six per cent and made an intraday high of Rs 272.50 on BSE.